Pontiff's has led a EUR87 million Series A funding round in biotech company Emergence Therapeutics.

Existing and new investors also participated along with the Emergence Therapeutics management team which was advices by ARQIS.

Proceeds from this funding round will be used to advance the company’s next-generation antibody drug conjugate (ADC) targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs. Antibody drug conjugates are among the most promising areas of research in the fight against cancer.